Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 5/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090271 | 0.81 | TTK (0.41) | TTKMAPK8 | |
| SCHEMBL4090306 | 0.81 | TTK (0.41) | TTKMAPK8 | |
| SCHEMBL4079849 | 0.79 | HRH3 (0.43) | KDM4ETTKMAPK8 | |
| SCHEMBL4079848 | 0.79 | HRH3 (0.43) | KDM4ETTKMAPK8 | |
| SCHEMBL4169025 | 0.79 | MCHR1 (0.44) | KDM4E | |
| SCHEMBL4084403 | 0.78 | LRRK2 (0.33) | TTKMAPK8LRRK2 | |
| SCHEMBL4183566 | 0.78 | JAK2 (0.41) | — | |
| SCHEMBL4183563 | 0.78 | JAK2 (0.41) | — | |
| SCHEMBL5819665 | 0.77 | CHEK1 (0.38) | CHEK1KDM4ETTKMAPK8CHRNB1 | |
| SCHEMBL4083943 | 0.77 | CHEK1 (0.38) | CHEK1KDM4ETTKMAPK8CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CHEK1 322/4885KDM4E 3468/4885TTK 401/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CHEK1 321/4885KDM4E 3359/4885TTK 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.